413 related articles for article (PubMed ID: 20206139)
41. Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine.
Constantino L; Paixão P; Moreira R; Portela MJ; Do Rosario VE; Iley J
Exp Toxicol Pathol; 1999 Jul; 51(4-5):299-303. PubMed ID: 10445386
[TBL] [Abstract][Full Text] [Related]
42. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.
Marcucci KA; Pearce RE; Crespi C; Steimel DT; Leeder JS; Gaedigk A
Drug Metab Dispos; 2002 May; 30(5):595-601. PubMed ID: 11950793
[TBL] [Abstract][Full Text] [Related]
43. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes.
Staack RF; Paul LD; Springer D; Kraemer T; Maurer HH
Biochem Pharmacol; 2004 Jan; 67(2):235-44. PubMed ID: 14698036
[TBL] [Abstract][Full Text] [Related]
44. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.
Nakamura K; Ariyoshi N; Yokoi T; Ohgiya S; Chida M; Nagashima K; Inoue K; Kodama T; Shimada N; Kamataki T
Biochem Biophys Res Commun; 2002 May; 293(3):969-73. PubMed ID: 12051754
[TBL] [Abstract][Full Text] [Related]
45. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
47. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen.
Dong H; Haining RL; Thummel KE; Rettie AE; Nelson SD
Drug Metab Dispos; 2000 Dec; 28(12):1397-400. PubMed ID: 11095574
[TBL] [Abstract][Full Text] [Related]
48. Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites.
Mürdter TE; Kerb R; Turpeinen M; Schroth W; Ganchev B; Böhmer GM; Igel S; Schaeffeler E; Zanger U; Brauch H; Schwab M
Hum Mol Genet; 2012 Mar; 21(5):1145-54. PubMed ID: 22108178
[TBL] [Abstract][Full Text] [Related]
49. The role of cytochrome P450 2D6 in the metabolism of moclobemide.
Härtter S; Dingemanse J; Baier D; Ziegler G; Hiemke C
Eur Neuropsychopharmacol; 1996 Aug; 6(3):225-30. PubMed ID: 8880082
[TBL] [Abstract][Full Text] [Related]
50. Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice.
Felmlee MA; Lon HK; Gonzalez FJ; Yu AM
Drug Metab Dispos; 2008 Feb; 36(2):435-41. PubMed ID: 18048490
[TBL] [Abstract][Full Text] [Related]
51. In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor.
Obach RS; Margolis JM; Logman MJ
Drug Metab Pharmacokinet; 2007 Oct; 22(5):336-49. PubMed ID: 17965517
[TBL] [Abstract][Full Text] [Related]
52. Metabolism of sumatriptan revisited.
Pöstges T; Lehr M
Pharmacol Res Perspect; 2023 Feb; 11(1):e01051. PubMed ID: 36655303
[TBL] [Abstract][Full Text] [Related]
53. Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells.
Evert B; Eichelbaum M; Haubruck H; Zanger UM
Naunyn Schmiedebergs Arch Pharmacol; 1997 Mar; 355(3):309-18. PubMed ID: 9089660
[TBL] [Abstract][Full Text] [Related]
54. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent.
Lussenburg BM; Keizers PH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2005 Oct; 70(8):1253-61. PubMed ID: 16135359
[TBL] [Abstract][Full Text] [Related]
55. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
Vuong C; Xie LH; Potter BM; Zhang J; Zhang P; Duan D; Nolan CK; Sciotti RJ; Zottig VE; Nanayakkara NP; Tekwani BL; Walker LA; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Smith B; Marcsisin SR
Antimicrob Agents Chemother; 2015 Jul; 59(7):3864-9. PubMed ID: 25870069
[TBL] [Abstract][Full Text] [Related]
56. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
Coleman T; Ellis SW; Martin IJ; Lennard MS; Tucker GT
J Pharmacol Exp Ther; 1996 May; 277(2):685-90. PubMed ID: 8627546
[TBL] [Abstract][Full Text] [Related]
57. Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice.
Shen HW; Yu AM
Drug Metab Lett; 2009 Dec; 3(4):234-41. PubMed ID: 19995332
[TBL] [Abstract][Full Text] [Related]
58. Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes.
Storelli F; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):170-180. PubMed ID: 30192434
[TBL] [Abstract][Full Text] [Related]
59. Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS.
Michely JA; Helfer AG; Brandt SD; Meyer MR; Maurer HH
Anal Bioanal Chem; 2015 Oct; 407(25):7831-42. PubMed ID: 26297461
[TBL] [Abstract][Full Text] [Related]
60. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.
Ring BJ; Eckstein JA; Gillespie JS; Binkley SN; VandenBranden M; Wrighton SA
J Pharmacol Exp Ther; 2001 Jun; 297(3):1044-50. PubMed ID: 11356927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
